Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

This study has been completed.
Sponsor:
Collaborators:
Myeloproliferative Disorders-Research Consortium
National Cancer Institute (NCI)
Roche Pharma AG
Information provided by (Responsible Party):
Ronald Hoffman, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier:
NCT01259817
First received: December 6, 2010
Last updated: January 10, 2017
Last verified: January 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2016
  Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)